Please login to the form below

Not currently logged in
Email:
Password:

sevelamer

This page shows the latest sevelamer news and features for those working in and with pharma, biotech and healthcare.

Sanofi warns of difficult few months as diabetes sales slump

Sanofi warns of difficult few months as diabetes sales slump

The loss of patent protection for kidney disease drug Renvela/Renagel (sevelamer) also took its toll, according to chief executive Olivier Brandicourt, the architect of the turnaround plan at Sanofi, who ... Brandicourt said that overall the company’s

Latest news

  • Generic competition for Sanofi's Renvela hits UK market Generic competition for Sanofi's Renvela hits UK market

    Teva UK and a number of other generic companies have launched their versions of Sanofi's Renvela (sevelamer carbonate), following the expiry of the drug's patent in the country. ... Renvela is a next-generation version of Renagel (sevelamer hydrochloride)

  • Orphan drugs in latest CHMP recommendations Orphan drugs in latest CHMP recommendations

    Completing the positive opinions were two new informed consent applications: Sevelamer carbonate Zentiva (sevelamer) from Genzyme for the control of hyperphosphataemia in adults receiving haemodialysis or peritoneal dialysis and Rasagiline

  • Trials and tribulations

    Sevelamer carbonate. Renvela (Genzyme Corporation). Hypophosphataemia. US. Hydrocodone/ibuprofen. Ibudone (ProEthic Pharmaceuticals).

  • News in brief, May 02, 2007

    The tablet facility supplies the global market with Renagel (sevelamer), a phosphate binder used in the treatment of chronic kidney disease for patients on dialysis.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell - Cake

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics